Tamtam Try Tamtam free
GoodRx logo

GoodRx account plan

Healthcare cost savings app

At a glance

GoodRx (Nasdaq: GDRX) is a US prescription savings platform with $796.9 million of FY2025 revenue, shifting toward pharma and subscriptions.

GoodRx Holdings, Inc. runs a consumer-focused digital healthcare platform in the United States: a prescription price-comparison marketplace, subscriptions and Pharma Direct, which sells advertising and consumer affordability programs to drug manufacturers. All revenue is generated in the United States. For FY2025 (calendar year) it reported revenue of $796.9 million, net income of $30.4 million and Adjusted EBITDA of $270.5 million, with 697 full-time employees at December 31, 2025. It is listed on Nasdaq under GDRX and is a "controlled company": the parties to its stockholders agreement, which include Silver Lake, Francisco Partners and Idea Men, LLC, held about 93.8% of voting power at December 31, 2025. Wendy Barnes is Chief Executive Officer.

Business units

Strategic priorities

Scale Pharma Direct
The company wants more manufacturers, more brands per manufacturer and more solutions per manufacturer. On the Q2 2026 call it counted more than 135 consumer direct pricing programs and raised its 2026 Pharma Direct growth expectation to more than 70%.
Make subscriptions the primary consumer offer
GoodRx Companion is now the primary subscription offering, at $14.99 per month or $9.99 per month on an annual plan, with 200 free generic medications. Subscriptions become the primary call to action on the homepage and price pages.
Direct contracts with retail pharmacies
The company has direct contracts with 9 of the top 10 retail pharmacies and had 6 of the top 10 live on its e-commerce platform at the end of 2025. E-commerce is live at nearly 6,000 pharmacies as of the Q2 2026 call.
Employer Direct
A platform that pairs employers' existing benefits with integrated cash pricing, starting with GLP-1 medications. Partners are expected to go live in Q4 and into Q1.
2026 guidance (raised in August)
Full-year 2026 revenue of $790 million to $805 million and Adjusted EBITDA of $240 million to $250 million, with a return to year-over-year revenue growth expected earlier than previously anticipated. These figures were given before the later restatement of Q1 and Q2 2026.
AI in the operating model
Management is hiring talent and investing to embed AI in how it builds and scales the platform, aiming to speed product delivery and support operating leverage.

Latest results

For the quarter ended June 30, 2026, as originally filed on August 5, 2026, revenue was $200.4 million against $203.1 million a year earlier, and Adjusted EBITDA was $63.7 million (31.8% margin) against $69.4 million. Pharma Direct revenue was $61,628 thousand (up 76%), subscription revenue $28,514 thousand (up 39%) and prescription transactions revenue $106,390 thousand (down 26%). Monthly Active Consumers were 5.0 million against 5.7 million in Q2 2025. On October 27, 2026 the Audit and Risk Committee concluded that the Q1 and Q2 2026 financial statements should no longer be relied upon because Pharma Direct revenue was understated. Preliminary restated total revenue was $222,684 thousand for Q2 2026 and $424,190 thousand for the six months, and the amounts remain subject to change.

Investments and deals

Acquisitions
VCRx, a prescription savings business, for $30.0 million in cash on January 13, 2025, and ScriptDrop, a prescription delivery technology platform, for $13.4 million in cash on October 16, 2025.
Subscription and Pharma Direct spending
The company says it is directing more product and marketing investment toward subscriptions and Pharma Direct. Its customer acquisition costs for new subscribers are described as below industry benchmarks, so it plans to increase brand and performance marketing where unit economics are strong.
Capital position
Cash was $296.1 million at June 30, 2026, with $80.4 million available under an $88.0 million revolver. A term loan of $495.0 million of principal was outstanding at December 31, 2025, due July 2029.

Challenges and risks

Falling prescription transactions
Revenue in this line fell 6% in FY2025 and 26% in Q2 2026 as originally filed, with Monthly Active Consumers down on store closures, the Rite Aid bankruptcy and a volume reduction in one integrated savings program.
Lower unit economics
Management describes a deliberate reduction of fees negotiated with retail and PBM partners for longer-term durability, a headwind in the mid-single digits as a percentage of consolidated revenue.
Restatement and internal controls
The company expects to file amended Forms 10-Q for the first two quarters of 2026 and currently expects to report one or more material weaknesses in internal control over financial reporting.
Dependence on PBMs and pharmacy chains
The three largest PBM customers accounted for 22% of 2025 revenue. The 10-K flags consolidation among PBMs and national pharmacy chains as a risk to pricing.
Policy uncertainty around TrumpRx
GoodRx is an integration partner for manufacturers' cash prices on TrumpRx, but the 10-K says the impact of TrumpRx on its business is unclear and "may be significant".

What leadership says

“GoodRx has become one of the leading consumer access channels for GLP-1 medications in the U.S.”

Wendy Barnes, Chief Executive Officer · Q2 2026 earnings call, August 6, 2026

“While we are not discontinuing Gold, Companion is now our primary subscription offering with a broader nationwide pharmacy network, richer benefits and consistently lower prices.”

Wendy Barnes, Chief Executive Officer · Q2 2026 earnings call, August 6, 2026

“Brands used to be a loser at retail, and we are ensuring that it no longer is.”

Chris McGinnis, Chief Financial Officer · Q4 2025 earnings call, February 26, 2026

Where a supplier can help

Finance and revenue-recognition tooling
The restatement of Q1 and Q2 2026 for understated Pharma Direct revenue, and the expected material weaknesses, point to demand for revenue recognition, close and controls automation, and audit support.
Subscription growth and retention
With Companion as the primary subscription offering and subscription plans at 764 thousand, there is room for suppliers in acquisition funnels, billing, retention and reactivation, tied to the shift of marketing toward subscriptions.
Pharma Direct and Employer Direct delivery
Scaling more than 135 consumer direct pricing programs and a new employer pipeline creates needs in program operations, manufacturer reporting and benefits integration.
AI for workflow and product delivery
Management says it is hiring and investing to embed AI into the operating model, which opens room for tools that reduce manual work in engineering, operations and support.
Pharmacy e-commerce and delivery
E-commerce live at nearly 6,000 pharmacies and the ScriptDrop acquisition show active investment in digital fulfilment and delivery for retail partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like GoodRx?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about GoodRx

What does GoodRx do?

GoodRx runs a US digital healthcare platform where consumers find lower prescription prices and use free GoodRx codes at pharmacies. It also sells subscriptions to consumers and Pharma Direct affordability and advertising programs to drug manufacturers.

How much revenue does GoodRx make?

GoodRx reported FY2025 revenue of $796.9 million, up 1% from $792.3 million, with Adjusted EBITDA of $270.5 million (33.9% margin). Prescription transactions were 68% of revenue, Pharma Direct 19% and subscriptions 11%.

How many employees does GoodRx have?

GoodRx had 697 full-time employees at December 31, 2025, according to its 10-K.

Who owns and leads GoodRx?

Wendy Barnes is Chief Executive Officer. Silver Lake, Francisco Partners and Idea Men, LLC are parties to a stockholders agreement that held about 93.8% of voting power at December 31, 2025, making GoodRx a controlled company.

What is GoodRx's strategy?

It keeps the prescription marketplace as its foundation while investing in Pharma Direct, subscriptions such as GoodRx Companion, deeper retail pharmacy relationships and Employer Direct. It expects near-term pressure on prescription transactions revenue in 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)